BFEC
NVS icon

Benjamin F. Edwards & Company’s Novartis NVS Stock Holding History

Benjamin F. Edwards & Company’s Portfolio NVS Stock Details NVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$698K Buy
6,559
+232
+4% +$23.3K 0.01% 610
2024
Q1 		$612K Sell
6,327
-81
-1% -$8.3K 0.01% 617
2023
Q4 		$647K Buy
6,408
+377
+6% +$36.4K 0.01% 586
2023
Q3 		$614K Sell
6,031
-106
-2% -$10.8K 0.02% 476
2023
Q2 		$619K Buy
6,137
+58
+1% +$5.8K 0.02% 461
2023
Q1 		$559K Buy
6,079
+66
+1% +$5.76K 0.02% 464
2022
Q4 		$546K Sell
6,013
-9,519
-61% -$802K 0.02% 445
2022
Q3 		$1.18M Sell
15,532
-276
-2% -$22.9K 0.06% 286
2022
Q2 		$1.34M Buy
15,808
+455
+3% +$39.9K 0.06% 272
2022
Q1 		$1.35M Buy
15,353
+1,249
+9% +$108K 0.06% 294
2021
Q4 		$1.23M Sell
14,104
-458
-3% -$38K 0.05% 308
2021
Q3 		$1.19M Buy
14,562
+529
+4% +$47.6K 0.06% 299
2021
Q2 		$1.28M Buy
14,033
+12
+0.1% +$1.07K 0.07% 288
2021
Q1 		$1.2M Buy
14,021
+489
+4% +$43.9K 0.06% 299
2020
Q4 		$1.28M Sell
13,532
-1,176
-8% -$103K 0.08% 264
2020
Q3 		$1.28M Buy
14,708
+83
+0.6% +$7.19K 0.09% 239
2020
Q2 		$1.28M Buy
14,625
+300
+2% +$25.9K 0.09% 222
2020
Q1 		$1.18M Buy
14,325
+2,302
+19% +$205K 0.1% 205
2019
Q4 		$1.14M Buy
12,023
+4,579
+62% +$411K 0.08% 248
2019
Q3 		$647K Buy
7,444
+2,164
+41% +$194K 0.05% 321
2019
Q2 		$482K Sell
5,280
-706
-12% -$59.8K 0.04% 361
2019
Q1 		$516K Sell
5,986
-562
-9% -$45.1K 0.05% 326
2018
Q4 		$503K Buy
6,548
+679
+12% +$52.9K 0.05% 310
2018
Q3 		$453K Buy
5,869
+459
+8% +$33.9K 0.04% 343
2018
Q2 		$366K Sell
5,410
-11,746
-68% -$811K 0.04% 380
2018
Q1 		$1.24M Sell
17,156
-8,215
-32% -$625K 0.13% 168
2017
Q4 		$1.91M Buy
25,371
+969
+4% +$73.1K 0.2% 123
2017
Q3 		$1.88M Sell
24,402
-1,321
-5% -$99.8K 0.23% 102
2017
Q2 		$1.92M Buy
25,723
+28
+0.1% +$1.98K 0.25% 99
2017
Q1 		$1.71M Buy
25,695
+237
+0.9% +$15.8K 0.25% 93
2016
Q4 		$1.66M Buy
25,458
+13,720
+117% +$890K 0.27% 88
2016
Q3 		$831K Sell
11,738
-38
-0.3% -$2.77K 0.15% 154
2016
Q2 		$871K Buy
11,776
+1,277
+12% +$88.2K 0.17% 134
2016
Q1 		$681K Buy
10,499
+439
+4% +$29.9K 0.14% 159
2015
Q4 		$776K Buy
10,060
+468
+5% +$37.2K 0.17% 137
2015
Q3 		$790K Buy
9,592
+1,466
+18% +$130K 0.17% 129
2015
Q2 		$716K Buy
8,126
+611
+8% +$56.1K 0.14% 154
2015
Q1 		$664K Buy
7,515
+1,785
+31% +$158K 0.14% 160
2014
Q4 		$476K Sell
5,730
-166
-3% -$13.8K 0.11% 182
2014
Q3 		$497K Buy
5,896
+1,218
+26% +$98.5K 0.12% 170
2014
Q2 		$379K Buy
4,678
+722
+18% +$56.8K 0.1% 205
2014
Q1 		$301K Buy
3,956
+59
+2% +$4.3K 0.08% 217
2013
Q4 		$281K Sell
3,897
-86
-2% -$5.98K 0.09% 205
2013
Q3 		$274K Sell
3,983
-215
-5% -$14.2K 0.1% 188
2013
Q2 		$266K Buy
+4,198
New +$273K 0.11% 178

Other funds holding NVS

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CCM
Cullen Capital Management New York $10.2B AUM 27.15% 1-Year Est. Return

Benjamin F. Edwards & Company's NVS Position: Q2 2024 in Review

Benjamin F. Edwards & Company increased its Novartis (NVS) stake by 3.7% in Q2 2024, buying an estimated $23.3K and bringing the position to 6,559 shares worth $698K. The position accounts for 0.01% of the portfolio, ranked #610.

Benjamin F. Edwards & Company first reported a position in NVS in Q2 2013 and has held it in 45 quarters since. The position peaked at $1.92M in Q2 2017. 1,307 funds tracked by Wall St. Rank hold NVS as of Q2 2024.

  • Benjamin F. Edwards & Company held 6,559 shares of Novartis worth $698K as of Q2 2024.
  • Benjamin F. Edwards & Company bought 232 Novartis shares in Q2 2024, an estimated $23.3K.
  • Novartis made up 0.01% of Benjamin F. Edwards & Company's portfolio in Q2 2024, its #610 holding.
  • Benjamin F. Edwards & Company first reported a position in Novartis in Q2 2013 and has held it in 45 quarters since.
  • Benjamin F. Edwards & Company's Novartis position peaked at $1.92M in Q2 2017.
  • 1,307 funds tracked by Wall St. Rank held Novartis as of Q2 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2024, filed 12 Aug 2024.